50–75 mg ×2/day of standardized extract WITHOUT alkaloids.
⏱ 3 min read
Petasites hybridus, known in English as butterbur, is a perennial plant common along riverbanks and in wetlands of Europe, Asia, and North America, whose rhizomes and leaves have traditionally been used for multiple indications; in recent decades, several standardized extracts (especially Petadolex) achieved notable clinical support as a prophylactic treatment for migraine and as an antihistamine for allergic rhinitis, positioning it as one of the herbal remedies with the strongest clinical data for these specific indications.
However, the clinical picture of petasites has changed significantly in recent years: several reports of hepatotoxicity associated with petasites extracts (some serious, including cases of liver failure requiring transplantation) led regulatory agencies in several countries (the United Kingdom, Germany, Switzerland, and the United States in practice) to restrict or withdraw the products from the market or to issue specific warnings; the American Academy of Neurology, which had recommended petasites as a prophylactic treatment for migraine with a level A rating of evidence in 2012, subsequently withdrew this specific recommendation in light of emerging safety concerns, making it one of the few herbal remedies whose support has been formally withdrawn by clinical societies.
The indication with the strongest clinical support was migraine prophylaxis: several randomized trials with Petadolex (a standardized petasites extract free of hepatotoxic pyrrolizidine alkaloids) at 75 mg twice daily for 3-4 months demonstrated significant reductions in migraine attack frequency (50-60 percent reduction), with magnitudes comparable to those of some pharmaceutical prophylactic antimigraine drugs such as propranolol or topiramate.
In seasonal allergic rhinitis, several European trials have documented efficacy comparable to cetirizine and fexofenadine (pharmacological antihistamines) with Petadolex doses of 50-75 mg twice daily during the period of allergen exposure, without the sedative effects characteristic of some classic antihistamines.
The fundamental problem with petasites is the natural presence of pyrrolizidine alkaloids (PAs) in unpurified preparations, a family of compounds with known hepatotoxicity and demonstrated carcinogenicity; modern industrial processes remove PAs to very low levels (Petadolex and similar products declare a content below 0.08 ppm), but several clinical cases of serious hepatotoxicity have appeared even with "purified" products marketed as safe, which suggests that the risk is not completely eliminated by standard purification and/or that other components of the extract may contribute to liver damage.
This concern led to the withdrawal of Petadolex from several European markets and to the current clinical recommendation that petasites should not be used routinely as a prophylactic treatment for migraine, especially when pharmaceutical alternatives with a better-established safety profile exist; people currently on chronic treatment with petasites should monitor liver function regularly and consider alternatives with their physicians.
Given the current regulatory and safety situation, the reasonable clinical position is to reserve petasites for specific situations (migraine refractory to other interventions, contraindication to alternatives) under strict medical supervision and with regular liver monitoring, and to use only products certified as free of pyrrolizidine alkaloids (an explicit manufacturer declaration with verifiable analysis); typical doses are 50-75 mg of standardized extract twice daily for 3-4 months as an initial trial.
The most important precaution is hepatotoxicity: people with preexisting liver disease, alcoholism, or viral hepatitis, or who take other hepatotoxic drugs (acetaminophen at high doses, methotrexate, isoniazid, amiodarone, others), should avoid petasites absolutely; signs suggestive of liver toxicity (jaundice, abdominal pain in the right upper quadrant, unusual fatigue, itching) during treatment require immediate discontinuation and urgent medical evaluation; people with an allergy to the Asteraceae family (ragweed, chrysanthemum, daisy) may have cross-reactions; it is contraindicated in pregnancy and breastfeeding; it is not recommended in children and adolescents; unpurified products or those of uncertain origin (which retain pyrrolizidine alkaloids at toxic levels) are absolutely contraindicated; given the pharmaceutical and nutritional alternatives available for migraine (propranolol, topiramate, magnesium, riboflavin, coenzyme Q10, feverfew) with better-established safety profiles, petasites has become a relegated second- or third-line option.
Information, not medical advice. Scientific evidence reflects the quality of the studies.